{"id":"https://openalex.org/W1817433628","doi":"https://doi.org/10.1586/17512433.2015.1075879","title":"Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration","display_name":"Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration","publication_year":2015,"publication_date":"2015-08-07","ids":{"openalex":"https://openalex.org/W1817433628","doi":"https://doi.org/10.1586/17512433.2015.1075879","mag":"1817433628","pmid":"https://pubmed.ncbi.nlm.nih.gov/26289225"},"language":"en","primary_location":{"id":"doi:10.1586/17512433.2015.1075879","doi":"https://doi.org/10.1586/17512433.2015.1075879","is_oa":false,"landing_page_url":"https://doi.org/10.1586/17512433.2015.1075879","pdf_url":null,"source":{"id":"https://openalex.org/S102962966","display_name":"Expert Review of Clinical Pharmacology","issn_l":"1751-2433","issn":["1751-2433","1751-2441"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Clinical Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069387283","display_name":"Thanh T. Nguyen","orcid":"https://orcid.org/0000-0001-6603-7007","observed_orcids":["https://orcid.org/0000-0001-6603-7007","https://orcid.org/0000-0002-0177-4230"]},"institutions":[{"id":"https://openalex.org/I165779595","display_name":"The University of Melbourne","ror":"https://ror.org/01ej9dk98","country_code":"AU","type":"education","lineage":["https://openalex.org/I165779595"]},{"id":"https://openalex.org/I4210105949","display_name":"Centre for Eye Research Australia","ror":"https://ror.org/01sqdef20","country_code":"AU","type":"facility","lineage":["https://openalex.org/I4210105949"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Thanh T Nguyen","raw_affiliation_strings":["a Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"a Centre for Eye Research Australia, University of Melbourne, Melbourne, Victoria, Australia","institution_ids":["https://openalex.org/I165779595","https://openalex.org/I4210105949"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5051997081","display_name":"Robyn H. Guymer","orcid":"https://orcid.org/0000-0002-9441-4356","observed_orcids":["https://orcid.org/0000-0002-9441-4356"]},"institutions":[{"id":"https://openalex.org/I165779595","display_name":"The University of Melbourne","ror":"https://ror.org/01ej9dk98","country_code":"AU","type":"education","lineage":["https://openalex.org/I165779595"]}],"countries":["AU"],"is_corresponding":true,"raw_author_name":"Robyn Guymer","raw_affiliation_strings":["University of Melbourne"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Melbourne","institution_ids":["https://openalex.org/I165779595"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5051997081"],"corresponding_institution_ids":["https://openalex.org/I165779595"],"apc_list":null,"apc_paid":null,"fwci":4.4575,"has_fulltext":false,"cited_by_count":37,"citation_normalized_percentile":{"value":0.94248757,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":98},"biblio":{"volume":"8","issue":"5","first_page":"541","last_page":"548"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9976000189781189,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/conbercept","display_name":"conbercept","score":0.9959999918937683},{"id":"https://openalex.org/keywords/neovascular-age-related-macular-degeneration","display_name":"neovascular age-related macular degeneration","score":0.9990000128746033},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.968999981880188},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.7620000243186951},{"id":"https://openalex.org/keywords/pegaptanib","display_name":"pegaptanib","score":0.8899999856948853},{"id":"https://openalex.org/keywords/ranibizumab","display_name":"ranibizumab","score":0.9919999837875366},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.9940000176429749},{"id":"https://openalex.org/keywords/aflibercept","display_name":"aflibercept","score":0.9890000224113464},{"id":"https://openalex.org/keywords/drug-efficacy-and-safety","display_name":"drug safety and efficacy","score":0.5920000076293945}],"concepts":[{"id":"https://openalex.org/C2776403814","wikidata":"https://www.wikidata.org/wiki/Q27429789","display_name":"Macular degeneration","level":2,"score":0.947534441947937},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9452719688415527},{"id":"https://openalex.org/C2777512022","wikidata":"https://www.wikidata.org/wiki/Q409935","display_name":"Pegaptanib","level":5,"score":0.9401552677154541},{"id":"https://openalex.org/C2781100027","wikidata":"https://www.wikidata.org/wiki/Q414270","display_name":"Ranibizumab","level":4,"score":0.8690972328186035},{"id":"https://openalex.org/C2778749236","wikidata":"https://www.wikidata.org/wiki/Q4689286","display_name":"Aflibercept","level":4,"score":0.8275023698806763},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.69819176197052},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.541983962059021},{"id":"https://openalex.org/C2781359195","wikidata":"https://www.wikidata.org/wiki/Q5105209","display_name":"Choroidal neovascularization","level":3,"score":0.4620243012905121},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4387034773826599},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3606451749801636},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3415921628475189},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.08379772305488586}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008268","descriptor_name":"Macular Degeneration","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011993","descriptor_name":"Recombinant Fusion Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020256","descriptor_name":"Choroidal Neovascularization","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D020256","descriptor_name":"Choroidal Neovascularization","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1586/17512433.2015.1075879","doi":"https://doi.org/10.1586/17512433.2015.1075879","is_oa":false,"landing_page_url":"https://doi.org/10.1586/17512433.2015.1075879","pdf_url":null,"source":{"id":"https://openalex.org/S102962966","display_name":"Expert Review of Clinical Pharmacology","issn_l":"1751-2433","issn":["1751-2433","1751-2441"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Review of Clinical Pharmacology","raw_type":"journal-article"},{"id":"pmid:26289225","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/26289225","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert review of clinical pharmacology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":79,"referenced_works":["https://openalex.org/W44172448","https://openalex.org/W143057823","https://openalex.org/W183147717","https://openalex.org/W187022904","https://openalex.org/W1481978003","https://openalex.org/W1493672163","https://openalex.org/W1500728559","https://openalex.org/W1539571840","https://openalex.org/W1587020653","https://openalex.org/W1604870194","https://openalex.org/W1624346216","https://openalex.org/W1639199029","https://openalex.org/W1802218256","https://openalex.org/W1875554126","https://openalex.org/W1965037168","https://openalex.org/W1966486839","https://openalex.org/W1966709403","https://openalex.org/W1968194636","https://openalex.org/W1972242350","https://openalex.org/W1972642682","https://openalex.org/W1978139448","https://openalex.org/W1980725734","https://openalex.org/W1981612052","https://openalex.org/W1983763042","https://openalex.org/W1984265335","https://openalex.org/W1994970571","https://openalex.org/W1996870435","https://openalex.org/W1999143095","https://openalex.org/W2000292756","https://openalex.org/W2000774921","https://openalex.org/W2004117352","https://openalex.org/W2004196006","https://openalex.org/W2015344488","https://openalex.org/W2018552583","https://openalex.org/W2020761135","https://openalex.org/W2025869445","https://openalex.org/W2030615367","https://openalex.org/W2043863730","https://openalex.org/W2049612319","https://openalex.org/W2049827480","https://openalex.org/W2051268134","https://openalex.org/W2051842051","https://openalex.org/W2057379707","https://openalex.org/W2057594701","https://openalex.org/W2061182836","https://openalex.org/W2068226356","https://openalex.org/W2075634939","https://openalex.org/W2077129920","https://openalex.org/W2077891356","https://openalex.org/W2084506573","https://openalex.org/W2085682483","https://openalex.org/W2085712747","https://openalex.org/W2094739999","https://openalex.org/W2095251825","https://openalex.org/W2098155102","https://openalex.org/W2108364254","https://openalex.org/W2113145680","https://openalex.org/W2118548020","https://openalex.org/W2123559545","https://openalex.org/W2124415048","https://openalex.org/W2126802692","https://openalex.org/W2131008692","https://openalex.org/W2131192872","https://openalex.org/W2133784172","https://openalex.org/W2137893922","https://openalex.org/W2154073405","https://openalex.org/W2154200023","https://openalex.org/W2154711032","https://openalex.org/W2160226180","https://openalex.org/W2161937920","https://openalex.org/W2166984623","https://openalex.org/W2169250157","https://openalex.org/W2193158077","https://openalex.org/W2317831656","https://openalex.org/W2322318138","https://openalex.org/W2324588265","https://openalex.org/W2612281319","https://openalex.org/W4241964533","https://openalex.org/W4251720370"],"related_works":["https://openalex.org/W2044852166","https://openalex.org/W4386843879","https://openalex.org/W2776333955","https://openalex.org/W3033555223","https://openalex.org/W4393242851","https://openalex.org/W1988252501","https://openalex.org/W1803161582","https://openalex.org/W2292143001","https://openalex.org/W3022464054","https://openalex.org/W1994011733"],"abstract_inverted_index":{"Age-related":[0],"macular":[1],"degeneration":[2],"(AMD)":[3],"is":[4,121],"a":[5,82,123],"progressive,":[6],"degenerative":[7],"disease":[8],"of":[9,26,38,48,56,58,101],"the":[10,23,34,49,54,99],"retina":[11],"that":[12,42],"occurs":[13],"with":[14,17],"increasing":[15],"incidence":[16],"age":[18],"and":[19,36,81,92,135],"ranks":[20],"third":[21],"among":[22],"global":[24],"causes":[25],"visual":[27],"impairment.":[28],"VEGF":[29,84],"has":[30],"been":[31],"implicated":[32],"in":[33,69,71,104,116],"development":[35],"progression":[37],"neovascular":[39,59,64,72,102,117],"AMD.":[40,118],"Drugs":[41],"block":[43],"VEGF,":[44],"leading":[45],"to":[46,108,131],"regression":[47],"abnormal":[50],"blood":[51],"vessels,":[52],"are":[53,74],"mainstay":[55],"treatment":[57,100],"AMD,":[60],"particularly":[61],"for":[62,98,114,125],"subfoveal":[63],"lesions.":[65],"Anti-VEGF":[66],"agents":[67],"currently":[68],"use":[70,115],"AMD":[73,103],"pegaptanib":[75],"(Macugen(\u00ae)),":[76],"ranibizumab":[77],"(Lucentis(\u00ae)),":[78],"bevacizumab":[79],"(Avastin(\u00ae))":[80],"soluble":[83],"receptor":[85],"decoy":[86],"aflibercept":[87],"(Eylea(\u00ae)).":[88],"Recently,":[89],"China":[90],"Food":[91],"Drug":[93],"Administration":[94],"have":[95],"approved":[96],"conbercept":[97],"China.":[105],"Conbercept":[106],"appears":[107],"offer":[109],"yet":[110],"another":[111],"anti-VEGF":[112],"drug":[113],"However,":[119],"there":[120],"still":[122],"need":[124],"large,":[126],"well-designed,":[127],"randomized":[128],"clinical":[129],"trials":[130],"ensure":[132],"its":[133],"safety":[134],"efficacy.":[136]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}